WPI: %COMPANY_NAME% Stock Quote & Analysis - Zacks.com

ESTIMATES
Detailed Estimates

85.26

                        NA: (NYSE: WPI)
                    
                                    $85.73
                                
                                    0.47 (0.55%)
                                
                                    Volume 1,316,666
                                
                                    Jan 23 04:02 PM ET
                                
Zacks Rank: NA  

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                    Zacks Rank
                                                                    Definition
                                                                    Annualized Return
                                                                
                                                                    #1
                                                                    Strong Buy
                                                                    26.6%
                                                                
                                                                    #2
                                                                    Buy
                                                                    18.71%
                                                                
                                                                    #3
                                                                    Hold
                                                                    10.12%
                                                                
                                                                    #4
                                                                    Sell
                                                                    4.32%
                                                                
                                                                    #5
                                                                    Strong Sell
                                                                    2.16%
                                                                
                                                                    S&P
                                                                    500
                                                                    9.93%
                                                                
                                                        Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
Overview Quote

                            Get Overview Quote for:
                            
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
WPI Chart  by YCharts

                Earnings Estimates
            
                            No data available for WPI
                            
    Zacks Commentary
    
MedTech Industry Stock Outlook - Jan 2013Jan 29, 2013
Canada Approves Forest's BystolicJan 22, 2013
Stock Market News for January 10, 2013Jan 10, 2013
Forest Settles with GlenmarkJan 09, 2013
Stock Market News for January 8, 2013Jan 08, 2013
Impax Launches Opana ER GenericJan 07, 2013
Watson's Generic Product ApprovedJan 07, 2013
Tough Times Ahead for Endo HealthJan 04, 2013
More WPI Zacks Commentary

                        News
                    
Generic Drugs Will Hit Pharmaceuticals Hard in 2013 - BenzingaMar 14, 2013
Goodbye, Watson Pharmaceuticals -- Hello, Actavis - TheMotleyFoolJan 24, 2013
Do Generic-Drug Makers Belong in Your Portfolio? - TheMotleyFoolJan 23, 2013
Watson Pharma Buys Uteron Pharma SA - BenzingaJan 23, 2013
Watson Pharma Buys Uteron Pharma for $150 Million - TheMotleyFoolJan 23, 2013
FTC: Pay-to-Delay Pharma Deals Cover $8.3 Billion in Revenue - YChartsJan 17, 2013
Stock Investing: Stocks End Mixed In Higher Volume - Investors Business DailyJan 15, 2013
Stocks Pare Losses In Afternoon; Apple Down Again - Investors Business DailyJan 15, 2013
See All News Stories on WPI

<a href="#"><img id="dart_image_2" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="728" height="90" border="0" alt="" /></a>                

                            Quick Links
                        
Services

                                            Premium Services
Zacks Rank
Personal Finance
Commentary
Education

                                        
My Account

                                            Manage Account
Update Profile
Subscriptions
Preferences
Login/Password Help
Upgrade to Premium

                                        
Resources

                                            Help
FAQs
Disclosure
Privacy Policy
Performance
Site Map

                                        
Client Support

                                            Contact Us
Share Feedback
About Zacks
Careers
Advertise
Media

                                        
Follow Us
Facebook
Twitter
Linkedin
RSS
You Tube
Zacks Research is Reported On:

                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                        
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.